Acute pancreatitis in the use of canagliflozin: A rare side-effect of the novel therapy for type 2 diabetes mellitus

Canagliflozin (Invokana) is an innovative treatment for type 2 diabetes mellitus (DM) approved in a new class acknowledged as sodium-glucose co-transporter 2 inhibitors. Acute pancreatitis is a very rare side effect with an incidence <1%. a 50-year-old white male with DM type 2 presented to the e...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivali, Narat, Thongprayoon, Charat, Cheungpasitporn, Wisit, Ungprasert, Patompong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513334/
https://www.ncbi.nlm.nih.gov/pubmed/26229348
http://dx.doi.org/10.4103/0976-0105.160753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4513334/
https://www.ncbi.nlm.nih.gov/pubmed/26229348
http://dx.doi.org/10.4103/0976-0105.160753

Ejemplares similares